FAIRFIELD, Conn.--(BUSINESS WIRE)--Nov. 17, 2005--IMS Health (NYSE: RX), the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced that its Board of Directors has authorized the company to buy up to 10 million IMS shares under a new stock repurchase program. The Board had previously authorized the repurchase of 10 million shares, of which 4.4 million remains outstanding, bringing the total number of shares currently authorized for repurchase to 14.4 million shares.
